JointHealth™ express   August 31, 2022

Let BC PharmaCare hear "Your Voice" on guselkumab (Tremfya™) for the treatment of psoriatic arthritis

Guselkumab (Tremfya™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about guselkumab for the treatment of psoriatic arthritis.

You can give input if you are a B.C. resident and have psoriatic arthritis, a caregiver to someone with psoriatic arthritis, or if your group represents people who live with psoriatic arthritis.

If you would like our help in providing your input, you can email your comments to or call us at 604-974-1366. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Monday, September 26 so that we may submit the questionnaire in time for the deadline.

The submission deadline is midnight on September 28, 2022. Patients and caregivers may give their input directly through the link below.

Please click on information sheet link below to learn more about guselkumab and the questionnaire link below to let BC PharmaCare hear Your Voice:

  • To view the information sheet for guselkumab for the treatment of psoriatic arthritis: click here
  • To complete the Questionnaire as a patient, caregiver, or patient group representative: click here